IPO - BIOXYTRAN, INC

Form Type: S-1/A

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225005972

Filing Summary: BIOXYTRAN, INC., a Nevada-based reporting company under the Securities Exchange Act of 1934, has filed an amendment to their registration statement on Form S-1/A with the SEC on February 11, 2025. This amendment primarily aims to include the legal opinion from their counsel, Witherspoon Brajcich McPhee, PLLC, regarding the legality of the securities to be offered. The company certifies that it meets all the requirements for filing on Form S-1 and indicates that it is classified as a smaller reporting company. The registration statement is part of the process to commence the proposed sale of securities to the public as soon as the statement is declared effective.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-05

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225004932

Filing Summary: Bioxytran, Inc. has filed an amendment to its registration statement on Form S-1 for an initial public offering (IPO). The document provides updated financial information and other disclosures specific to the offering. The registration indicates the intent to offer classes of common stock to raise capital for business operations and expansion. This filing reflects a strategic effort to enhance financial position and market presence, including adjustments from prior reporting periods to capture recent financial developments.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-22

Corporate Action: Ipo

Type: New

Accession Number: 000149315225003259

Filing Summary: BIOXYTRAN, INC filed a Form S-1 on January 22, 2025, indicating its intention to pursue an Initial Public Offering (IPO). The filing includes detailed financial statements, risks associated with the business, and a description of the company's operations. Key points include the intended use of proceeds from the offering which may be directed towards research and development as well as administrative expenses. The company outlines its growth strategy, market position, and current financial health, highlighting previous funding rounds and existing debts. Additionally, the filing addresses potential risks related to market conditions and competition within the biotechnology sector.

Document Link: View Document